Immunex Will Collect Enbrel Juvenile RA Safety/Efficacy Data For Three Years

Immunex has committed to collecting safety and efficacy data of Enbrel in at least 500 juvenile rheumatoid arthritis patients for a minimum of three years, according to FDA's May 27 approval letter for the new arthritis indication.